Abstract 5771
Background
Hyponatremia, usually defined as the sodium serum level < 135 mEq/l (mmol/l), is a common electrolyte disorder in the clinical practice.1 Despite its often benign course, it can rapidly evolve into a life threatening condition mainly due to neurological symptoms. Moreover, in cancer patients, hyponatremia is significantly associated with reduced overall survival.2 In cancer patients hyponatremia can occur due to malignancy as well as chemotherapy.3 Many chemotherapy drugs have been reported to induce hyponatremia.4 This study aims to determine which chemotherapeutic drugs used in hematological patients are mostly associated with hyponatremia.
Methods
This study analyzed retrospectively the data from 189 patients with diagnosed haematological malignancies that developed hyponatremia while undergoing chemotherapy. The period of observation was determined to start at the first day of a chemotherapy cycle until the 3rd day after the end of a cycle. For the purpose of this study, hyponatremia was defined as serum sodium level < 135 mEq/l (mmol/l).
Results
In our cohort of 189 patients with hyponatremia the most predominant hematological malignancy was Multiple Myeloma, which was present in 56 (29.6%) of the included patients and was followed by diffuse large B-cell Lymphoma with 34 (13.2%) patients. The median age of the studied cohort was 68 years (range 33-84 years).The mean value of serum sodium was 130.4 ± 0.27 mEq/l. 42 (22.4 %) patients had hyponatremia in the 4th cycle of the chemotherapy, with 101 (53.4%) patients developing hyponatremia in the first 4 cycles of the chemotherapy. From all patients with hyponatremia (n = 189), 43 (22.7%) received Cyclophosphamide, 38 (20.1%) Vincristine, 85 (44.9%) Cyclophosphamide and Vincristine as part of a combination, 20 (10.5%) Methothrexate, 18 (9.5%) Cisplatin and 8 (4.2%) Daratumumab.
Conclusions
Patient with hematological malignancies are at increased risk of hyponatremia possibly induced by chemotherapy. The combination regimens seem to increase the risk of developing hyponatremia substantially. In which way the occurrence of hyponatremia depends on cofactors such as infusion schemas or tumor lysis has to be evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
1937 - Resection Of High-Grade Large Soft Tissue Sarcoma With Adequate Wide Margin Can Lead To Good Local Control Without Adjuvant Radiotherapy
Presenter: Toshiyuki Kunisada
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract